Hans T. Schambye
At a glance: Hans T. Schambye is CEO at Damora Therapeutics (DMRA). Their latest SEC Form 4, filed Jan 6, 2026, reported a sale of $15K. On file: 0 purchase lines ($0) and 1 sale line ($15K).
Disclosed holdings: about $112K of DMRA stock: 4,682 shares reported on their latest Form 4 (filed Jan 6, 2026), valued at the Nov 19, 2026 close of $23.91. This counts only DMRA shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
CEO at Galecto, Inc. (DMRA)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Hans T. Schambye's InsiderPrint
4 trades from SEC Form 4 filings, 2021 to 2026, drawn as one fingerprint.
Reading this print: Mostly buys, trading about once a year, typically $15K a trade.
- Bump outward: a purchase (3)
- Dent inward: a sale (1)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Donald A. McGovern Jr.Director · CARS · 99% match
- Robert Taglich10% Owner · INLX · 99% match
- Carol P. SandersDirector · RNR · 99% match
- Georgia ErbezCFO · CDXS · 99% match
- Roger D. ShannonCFO · LAKE · 99% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
Follow Hans T. Schambye
Get one email when Hans T. Schambye files a new purchase or sale. Free.
At most one email a day about Hans T. Schambye, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.